Visterra
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
Visterra
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
TL;DR
Stage: Clinical-stage biotechnology company
Focus: Antibody-based therapeutics; glycobiology/glycochemistry
Founded: 2007
Headquarters: Cambridge, Massachusetts
Acquisition: Acquired by Otsuka Holdings (announced 2018)
Company Overview
Problem Domain
Unmet needs in kidney diseases and other hard-to-treat diseases
Founded
2007
Industry
Research Services
Funding Track Record
Crunchbase lists Series C on Oct 5, 2017; amounts are obfuscated.
Investor Signal
“Backed by multiple institutional investors including Flagship Pioneering and the Bill & Melinda Gates Foundation; later acquired by Otsuka Holdings (announced 2018).”